How Do Ovarian Cancer Cells Develop Treatment Resistance with Help from Gut Bacteria?

Ovarian cancer remains one of the most common cancers in women and is usually diagnosed at an advanced stage. Despite treatment advances, survival has not improved substantially in recent decades.

Immune checkpoint inhibitor immunotherapies have been effective in many cancers by strengthening the immune system and activating cancer cells. However, while successful in cancers such as melanoma and urothelial carcinoma, they encounter resistance in ovarian cancer.

A Clever Cancer Strategy?

On February 11, 2025, Cancer Immunology Research published a study suggesting gut bacteria may play an important role in this resistance. The study found that the gut microbiota could contribute to immunotherapy failure.

Effects of the Gut Microbiota on Immunity

Previous research suggested an unhealthy gut microbiota may facilitate breast cancer spread. According to senior author Dr. Melanie Rutkowski of the University of Virginia Cancer Center, the gut microbiota plays a critical role in training our immune system from birth .

Rutkowski said, “We and other researchers are discovering that interactions between the microbiota and immune cells affect many vital processes, including metabolic health, organ function, and even communication between the gut and brain”.

Understanding how this relationship changes during diseases such as cancer is therefore important. Such research may enable new treatments that help the immune system destroy cancer cells.

Methods and Findings

Researchers examined flagella, structures that allow bacteria to move and contain a protein called flagellin . The study showed this protein may contribute to failure to respond to immune checkpoint therapy in patients with ovarian cancer.

The findings suggest ovarian tumors increase entry of flagellin from the gut , impairing immune cells' ability to fight cancer and increasing resistance. Dr. Rutkowski said, “As the gut wall becomes leaky, immune cells that recognize flagellin are reprogrammed to support tumor growth”.

Understanding this defense mechanism may open treatment opportunities. Initial laboratory tests showed that blocking flagellin-induced signaling disturbances could restore immune checkpoint therapy effectiveness.

Dr. Rutkowski added, “In mice whose immune cells could not recognize flagellin, immune checkpoint therapy provided long-term ovarian tumor control. Observing this response even with aggressive ovarian cancer cell lines suggests that inhibiting the pathway could improve clinical outcomes”.

A Changing Understanding

This study suggests that the gut microbiota may be important not only for general health but also for improving cancer treatment effectiveness. Researchers hope to use the findings to improve outcomes in ovarian and other cancers. Further research is nevertheless needed to enhance immune checkpoint therapy.

Immune recognition of flagellin causing immunotherapy failure contradicts our current understandingbecause flagellin is normally considered an immune-activating molecule. The following points help explain this apparent contradiction:

1. Flagellin Normally Strengthens Immune Responses

• Flagellin is a protein in bacterial flagella recognized by the immune system.
• Its recognition through sensing mechanisms such as Toll-like receptor 5 (TLR5) and the NOD-like receptor NLRC4 is a natural defense that triggers responses to infection.
• Flagellin activates immune cells, particularly dendritic cells and macrophages, increasing pro-inflammatory cytokine release and strengthening immunity.

2. A Different Mechanism Operates in Ovarian Cancer

The study suggests flagellin directs immunity toward supporting the tumor rather than fighting it. Several explanations are possible:

• Gut Leakage:
  • Ovarian tumors increase intestinal wall permeability, allowing flagellin to enter from the gut.
  • Flagellin that should normally remain in the intestine reaches the tumor microenvironment and misdirects immune cells.
• Reprogramming Immune Cells:
  • Immune cells recognizing flagellin are reprogrammed to support tumor growth rather than fight it.
  • Instead of suppressing tumors, they may generate an immunosuppressive response.
  • This may prevent immunotherapy medications from working effectively.

3. A Pattern Contrary to Conventional Immunology

Although flagellin generally increases immune activity, its suppressive role in the ovarian tumor environment contradicts conventional expectations.

• Immune cells would normally recognize and destroy cancer cells, but here flagellin appears to turn them into tumor-supporting cells.
• Immunotherapy failure may result from this flagellin-driven misdirection.

The researchers say further work is underway to understand why the mechanism is particularly influential in ovarian cancer.

Conclusion

This study suggests that the gut microbiota may be important not only for general health but also for improving cancer treatment effectiveness. Researchers hope to use the findings to improve outcomes in ovarian and other cancers. Further research is nevertheless needed to enhance immune checkpoint therapy.

In mouse models, immune cells unable to recognize flagellin significantly improved survival outcomes. Successfully translating these findings into clinical research could provide a promising new ovarian cancer treatment strategy. Understanding flagellin-immune interactions may be an important step toward improving immunotherapy and could support future approaches targeting the gut microbiota.